
Intuitive Surgical (ISRG) Stock Forecast & Price Target
Intuitive Surgical (ISRG) Analyst Ratings
Bulls say
Intuitive Surgical has demonstrated positive operational growth, with a 14% increase in Ion utilization and a 35% increase in SP utilization, further enhancing its overall installed base to 954 and 345 systems, respectively. The improved performance is complemented by a better-than-expected increase in US Da Vinci utilization, rising approximately 2% year-over-year, attributed to the higher performance of the newer D5 models. Additionally, the company has raised its gross margin guidance to 67-67.5%, indicating strong financial health driven by increased system placements and a favorable outlook on tariffs.
Bears say
The financial outlook for Intuitive Surgical appears negative due to several key factors impacting its operational and market performance. Revenue from services slightly missed expectations at $396 million, which reflects broader industry challenges such as hospital capital budget constraints and macroeconomic uncertainty that are leading to deferred purchasing decisions for robotic systems. Furthermore, the company faces resistance to adopting its newer robotic platforms in emerging markets, alongside pressure on instrument and accessories pricing driven by third-party instrument reprocessing, contributing to a less favorable operational environment.
This aggregate rating is based on analysts' research of Intuitive Surgical and is not a guaranteed prediction by Public.com or investment advice.
Intuitive Surgical (ISRG) Analyst Forecast & Price Prediction
Start investing in Intuitive Surgical (ISRG)
Order type
Buy in
Order amount
Est. shares
0 shares